About | Free Trial

Last Update

2016-06-13T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong J. McGovren?

Dr. J. McGovren Patrick

Vice President, Preclinical Development

ProNAi Therapeutics , Inc.

Direct Phone: (734) ***-****       

Email: j***@***.com

ProNAi Therapeutics , Inc.

46701 Commerce Center Drive

Plymouth, Michigan 48170

United States

Company Description

ProNAi Therapeutics, Inc. is dedicated to developing and commercializing a new class of therapies that target DNA to treat patients with cancer and other diseases. ProNAi Therapeutics, Inc. is leveraging its novel and proprietary nucleic acid-based inte... more

Find other employees at this company (56)

Background Information

Employment History

Principal

J Patrick McGovren LLC

Research Director, Clinical Pharmacology, Medical Development

Pfizer Inc

Numerous Senior Research and Management Posts

The Upjohn Company

Clinical Research Manager, Oncology Medical Affairs

Pharmacia

Education

Ph.D.

Web References (15 Total References)


ProNAi Therapeutics - Employing DNA to Silence Disease

www.pronai.com [cached]

J. Patrick McGovren, PhD VP, Preclinical Development Dr. McGovren is a longtime and well-known cancer research specialist, holding senior positions in big pharma oncology departments, as well as extensive consulting experience. Prior to joining ProNAi, Dr. McGovren was most recently Research Director, Clinical Pharmacology, Medical Development at Pfizer, following a term as Clinical Research Manager, Oncology Medical Affairs at Pharmacia. Between 1976 and 2000, Dr. McGovren held numerous senior research and management posts at Pharmacia & Upjohn.


Nanomed Pharmaceuticals Feed - News

www.nanomedpharm.com [cached]

In addition to Dr. Landis, key members serving on NanoMed's Scientific Advisory Board include: Russell J. Mumper, Ph.D., NanoMed co-founder, the John A. McNeill Distinguished Professor in the Molecular Pharmaceutics Division in the School of Pharmacy, and the first Director of the Center for Nanotechnology in Drug Delivery at The University of North Carolina at Chapel Hill; Michael Jay, Ph.D., NanoMed co-founder and professor in the Molecular Pharmaceutics division at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy; J. Patrick McGovren, Ph.D., VP, Preclinical Development of ProNai Therapeutics, Inc. and former Research Director, Clinical Pharmacology, Medical Development at Pfizer, Inc.; Charles Bibart, Ph.D., former Group Vice President - Active Pharmaceutical Ingredients for Pharmacia Corporation; and Douglas R. Morton, Jr., Ph.D.,formerGroup Vice President, Technology Acquisitions & Operations for Discovery Research in Pharmacia Corporation.


ProNAi Therapeutics - Employing DNA to Silence Disease

www.pronai.com [cached]

Patrick McGovren, PhDPrincipal, J. Patrick McGovren LLC, Kalamazoo, MI, Research Director, Clinical Pharmacology, Medical Development, Pfizer Corporation and past Clinical Research Manager, Oncology Medical Affairs, Pharmacia Corporation


Nanomed Pharm :: Read our News :: John B. Landis, Ph.D. Joins SAB

www.nanomedpharm.com [cached]

In addition to Dr. Landis, key members serving on NanoMed's Scientific Advisory Board include: Russell J. Mumper, Ph.D., NanoMed co-founder, the John A. McNeill Distinguished Professor in the Molecular Pharmaceutics Division in the School of Pharmacy, and the first Director of the Center for Nanotechnology in Drug Delivery at The University of North Carolina at Chapel Hill; Michael Jay, Ph.D., NanoMed co-founder and professor in the Molecular Pharmaceutics division at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy; J. Patrick McGovren, Ph.D., VP, Preclinical Development of ProNai Therapeutics, Inc. and former Research Director, Clinical Pharmacology, Medical Development at Pfizer, Inc.; Charles Bibart, Ph.D., former Group Vice President - Active Pharmaceutical Ingredients for Pharmacia Corporation; and Douglas R. Morton, Jr., Ph.D.,formerGroup Vice President, Technology Acquisitions & Operations for Discovery Research in Pharmacia Corporation.


Advisors and Collaborators

www.nanomedpharm.com [cached]

J. Patrick McGovren, Ph.D. is a longtime and well-known cancer research specialist, holding senior positions in big pharma oncology departments, as well as extensive consulting experience. He was involved in the discovery and/or development of nine clinically evaluated anti-tumor drugs and has significant clinical trial operations and IND/NDA submission experience. Currently, Dr. McGovren is VP, Preclinical Development of ProNai Therapeutics, Inc., an emerging biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAiĀ®, to advance a next generation of therapies for patients with cancer and other complex genetic diseases. Prior to joining ProNAi, Dr. McGovren was most recently Research Director, Clinical Pharmacology, Medical Development at Pfizer, following a term as Clinical Research Manager,Oncology Medical Affairs at Pharmacia. Between 1976 and 2000, Dr. McGovren held numerous senior research and management posts at Pharmacia & Upjohn.

Similar Profiles

Other People with this Name

Other people with the name McGovren

Shea McGovren
METHODIST SPORTS MEDICINE CENTER P.C

Matt McGovren
Wink.com

Kathryn McGovren
Pfizer Inc

Andrew McGovren
Kassius

John McGovren
Jasper Engines

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory